A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma

Autor: Guenther LM, Dharia NV, Ross L, Saur Conway A, Robichaud AL, Catlett JL, Wechsler C, Frank ES, Goodale AB, Church AJ, Tseng YY, Guha R, McKnight C, Janeway KA, Boehm JS, Mora J, Davis MI, Alexe G, Piccioni F, Stegmaier K

Publikováno v: CLINICAL CANCER RESEARCH
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu

PURPOSE: Novel targeted therapeutics have transformed the care of subsets of patients with cancer. In pediatric malignancies, however, with simple tumor genomes and infrequent targetable mutations, there have been few new FDA-approved targeted drugs.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::0e89c0c7bf876fd4c61c36ffab070477
http://fundanet.fsjd.org/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=15250

Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma: A Phase 2 Randomized Clinical Trial.

Autor: Gaspar N; Department of Oncology for Child and Adolescent, Gustave Roussy Cancer Campus, Villejuif, France., Hung GY; Department of Pediatrics, Taipei Veterans General Hospital, Taipei, Taiwan., Strauss SJ; London Sarcoma Service, University College London Hospital NHS Trust, London, United Kingdom., Campbell-Hewson Q; The Great North Children's Hospital, Royal Victoria Infirmary, Newcastle Upon Tyne, United Kingdom., Dela Cruz FS; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York., Glade Bender JL; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York., Koh KN; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Republic of Korea., Whittle SB; Department of Pediatrics, Texas Children's Cancer Center, Baylor College of Medicine, Houston., Chan GC; Department of Paediatrics and Adolescent Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China., Gerber NU; Department of Oncology, University Children's Hospital Zürich, Zürich, Switzerland., Palmu S; Tampere Center for Child, Adolescent and Maternal Health Research, Faculty of Medicine and Health Technology, Tampere University and University Hospital, Tampere, Finland., Morgenstern DA; Division of Haematology/Oncology, Department of Paediatrics, Hospital for Sick Children and University of Toronto, Toronto, Ontario, Canada., Longhi A; Chemotherapy Service, Istituto Ortopedico Rizzoli, Istituto di Ricovero e Cura a Carattere Scientifico, Bologna, Italy., Baecklund F; Paediatric Oncology Unit, Karolinska University Hospital Solna, Stockholm, Sweden., Lee JA; Center for Pediatric Cancer, National Cancer Center, Goyang, Republic of Korea., Locatelli F; Department of Pediatric Hematology and Oncology, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Pediatrico Bambino Gesù, Catholic University of the Sacred Heart, Rome, Italy., Márquez Vega C; Department of Pediatric Oncology, Hospital Virgen del Rocío, Seville, Spain., Janeway KA; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts., McCowage G; Cancer Centre for Children, The Children's Hospital at Westmead, Sydney, New South Wales, Australia., McCabe MG; Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom.; The Christie NHS Foundation Trust, Manchester, United Kingdom., Bidadi B; Clinical Research, Merck & Co Inc, Rahway, New Jersey., Huang J; Biostatistics, Eisai Inc, Nutley, New Jersey., McKenzie J; Oncology Business Group, Eisai Inc, Nutley, New Jersey., Okpara CE; Clinical Research, Eisai Ltd, Hatfield, United Kingdom., Bautista F; Hospital del Niño Jesús, Madrid, Spain.; Now with Princess Maxima Centrum for Pediatric Cancer, Utrecht, the Netherlands.

Publikováno v: JAMA oncology [JAMA Oncol] 2024 Oct 17. Date of Electronic Publication: 2024 Oct 17.

Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I).

Autor: Macy ME; Department of Pediatrics, University of Colorado and Children's Hospital Colorado, Aurora, CO., Mody R; CS Mott Children's Hospital and University of Michigan, Ann Arbor, MI., Reid JM; Mayo Clinic, Rochester, MN., Piao J; University of Southern California, Los Angeles, CA., Saguilig L; University of Southern California, Los Angeles, CA., Alonzo TA; University of Southern California, Los Angeles, CA., Berg SL; Texas Children's Cancer and Hematology Center, Baylor College of Medicine, Houston, TX., Fox E; St Jude Children's Research Hospital, Memphis, TN., Weigel BJ; University of Minnesota, Minneapolis, MN., Hawkins DS; Seattle Children's Hospital and University of Washington, Seattle, WA., Mooney MM; Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, MD., Williams PM; Frederick National Laboratory for Cancer Research, Frederick, MD., Patton DR; Center for Biomedical Informatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, MD., Coffey BD; Center for Biomedical Informatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, MD., Roy-Chowdhuri S; University of Texas, MD Anderson Cancer Center, Houston, TX., Takebe N; Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, MD., Tricoli JV; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Janeway KA; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA., Seibel NL; Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, MD., Parsons DW; Texas Children's Cancer and Hematology Center, Baylor College of Medicine, Houston, TX.

Publikováno v: JCO precision oncology [JCO Precis Oncol] 2024 Sep; Vol. 8, pp. e2400418.

Author Correction: Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer.

Autor: Forrest SJ; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA. Suzanne_Forrest@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. Suzanne_Forrest@dfci.harvard.edu., Gupta H; Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Ward A; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA., Li YY; Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Doan D; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA., Al-Ibraheemi A; Harvard Medical School, Boston, MA, USA.; Boston Children's Hospital, Boston, MA, USA., Alexandrescu S; Harvard Medical School, Boston, MA, USA.; Boston Children's Hospital, Boston, MA, USA., Bandopadhayay P; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Shusterman S; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Mullen EA; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Collins NB; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Chi SN; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Wright KD; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Kumari P; Dana-Farber Cancer Institute, Boston, MA, USA., Mazor T; Dana-Farber Cancer Institute, Boston, MA, USA., Ligon KL; Harvard Medical School, Boston, MA, USA.; Dana-Farber Cancer Institute, Boston, MA, USA.; Boston Children's Hospital, Boston, MA, USA.; Brigham and Women's Hospital, Boston, MA, USA., Shivdasani P; Brigham and Women's Hospital, Boston, MA, USA., Manam M; Boston Children's Hospital, Boston, MA, USA., MacConaill LE; Brigham and Women's Hospital, Boston, MA, USA., Ceca E; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA., Benich SN; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA., London WB; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA., Schilsky RL; American Society of Clinical Oncology, Alexandria, VA, USA., Bruinooge SS; American Society of Clinical Oncology, Alexandria, VA, USA., Guidry Auvil JM; National Cancer Institute, Bethesda, MD, USA., Cerami E; Dana-Farber Cancer Institute, Boston, MA, USA., Rollins BJ; Harvard Medical School, Boston, MA, USA.; Dana-Farber Cancer Institute, Boston, MA, USA.; Brigham and Women's Hospital, Boston, MA, USA., Meyerson ML; Harvard Medical School, Boston, MA, USA.; Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Lindeman NI; Weill Cornell Medical College, New York, NY, USA., Johnson BE; Harvard Medical School, Boston, MA, USA.; Dana-Farber Cancer Institute, Boston, MA, USA.; Brigham and Women's Hospital, Boston, MA, USA., Cherniack AD; Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Church AJ; Harvard Medical School, Boston, MA, USA.; Boston Children's Hospital, Boston, MA, USA., Janeway KA; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA. Katherine_Janeway@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. Katherine_Janeway@dfci.harvard.edu.

Publikováno v: Nature communications [Nat Commun] 2024 Aug 22; Vol. 15 (1), pp. 7218. Date of Electronic Publication: 2024 Aug 22.

Overcoming Systemic Barriers to Make Patient-Partnered Research a Reality.

Autor: Venkataraman V; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA., Martin-Giacalone BA; Washington University School of Medicine, St Louis, MO.; Alvin J. Siteman Cancer Center, St Louis, MO., Drake BF; Washington University School of Medicine, St Louis, MO.; Alvin J. Siteman Cancer Center, St Louis, MO., Salmi L; Beth Israel Deaconess Medical Center, Boston, MA., Claus EB; Department of Biostatistics, Yale School of Public Health, New Haven, CT.; Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA., Schuster ALR; The Ohio State University College of Medicine, Columbus, OH., Bridges JFP; The Ohio State University College of Medicine, Columbus, OH., Lenz HJ; Keck School of Medicine of USC, Los Angeles, CA.; Norris Comprehensive Cancer Center, Los Angeles, CA., Willman CL; Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN.; The University of New Mexico School of Medicine, Albuquerque, NM., Diehl D; Count Me In, The Broad Institute of MIT and Harvard, Boston, MA., Janeway KA; Harvard Medical School, Boston, MA.; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA., Mack JW; Harvard Medical School, Boston, MA.; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA., George S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Aug 02, pp. JCO2400347. Date of Electronic Publication: 2024 Aug 02.